Hostname: page-component-74656f9884-rngvg Total loading time: 0 Render date: 2026-11-04T21:44:34.031Z Has data issue: false hasContentIssue false

The potential roles of c-Jun N-terminal kinase (JNK) during the maturation and aging of oocytes produced by a marine protostome worm

Published online by Cambridge University Press:  16 October 2017

Stephen A. Stricker*
Affiliation:
Department of Biology, University of New Mexico, Albuquerque, NM 87131, USA.
Niharika Ravichandran
Affiliation:
Department of Biology, University of New Mexico, Albuquerque, NM 87131 USA.
*
All correspondence to: Stephen A. Stricker. Department of Biology, University of New Mexico, Albuquerque, NM 87131, USA. Tel: +1 505 2771883. Fax: +1 505 2770304. E-mail: sstr@um.edu
Rights & Permissions [Opens in a new window]

Summary

Previous investigations have indicated that c-Jun N-terminal kinase (JNK) regulates the maturation and aging of oocytes produced by deuterostome animals. In order to assess the roles of this kinase in a protostome, oocytes of the marine nemertean worm Cerebratulus were stimulated to mature and subsequently aged before being probed with phospho-specific antibodies against active forms of JNK and maturation-promoting factor (MPF). Based on blots of maturing oocytes, a 40-kD putative JNK is normally activated during germinal vesicle breakdown (GVBD), which begins at 30 min post-stimulation with seawater, whereas treating immature oocytes with JNK inhibitors downregulates both the 40-kD JNK signal and GVBD, collectively suggesting a 40-kD JNK may facilitate oocyte maturation. Along with this JNK activity, mature oocytes also exhibit high levels of MPF at 2 h post-stimulation. However, by ~6–8 h post-GVBD, mature oocytes lose the 40-kD JNK signal, and at ~20–30 h of aging, an ~48-kD phospho-JNK band arises as oocytes deactivate MPF and begin to lyse during a necroptotic-like mode of death. Accordingly, JNK inhibitors reduce the aging-related 48-kD JNK phosphorylation while maintaining MPF activity and retarding oocyte degradation. Such findings suggest that a 48-kD JNK may help deactivate MPF and trigger death. Possible mechanisms by which JNK activation either together with, or independently of, protein neosynthesis might stimulate oocyte degradation are discussed.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 2017 
Figure 0

Figure 1 (A) Immature prophase-arrested oocyte of Cerebratulus exhibiting a conspicuous germinal vesicle (GV) prior to stimulation of maturation. (B) A mature oocyte after stimulation by seawater to trigger GVBD. (C) Reduction in levels of seawater-induced GVBD caused by two JNK inhibitors SP600125 (SP) and AS601245 (AS). (D) Immunoblot probed with a phospho-JNK antibody to detect activated JNK, showing the apparent activation of a 40-kD JNK isoform during GVBD, which begins by 30 min post-stimulation with seawater (sw). (E) Phospho-JNK immunoblot, showing a marked reduction in the 40-kD putative JNK signal caused by treatment with JNK inhibitors (sp, as). bf = before GVBD is stimulated by incubating prophase-arrested oocytes in seawater. Scale bars = 50 µm.

Figure 1

Figure 2 (A) Interspecimen variation in the onset of aging-induced degradation for oocytes produced by five female (fem) worms. (B) Typical necroptotic-like morphology of degrading oocytes at ~30 h of aging, showing flattening and subsequent lysis without displaying classic apoptotic features of cell death. Scale bar = 50 µm.

Figure 2

Figure 3 (A–C) Phospho-JNK immunoblots of immature, mature, and aging oocytes, showing an increase in the 40-kD phosphorylation during seawater (sw)-induced maturation. In moderately aged oocytes, the 40-kD band is lost prior to the appearance of a 48-kD band around the time that most oocytes begin to degrade (~24–30 h); bf = before GVBD is stimulated by incubating prophase-arrested oocytes in seawater.

Figure 3

Figure 4 (A, B) Dose–response curves of varying JNK inhibitor concentrations (0–50 µM), showing the ability of SP600125 (sp) and AS601245 (as) to retard aging-induced oocyte degradation in seawater (sw). (C) Reductions in oocyte degradation levels at 30 h of aging are maximized when prophase-arrested oocytes are initially treated with a seawater (sw) solution of a JNK inhibitor (sw + sp, sw + as) [sp = 25 µM; as = 33 µM], rather than allowed to mature before adding the inhibitor (sw then sp, sw then as), suggesting JNK activation during maturation may facilitate subsequent aging-induced degradation. (D, E) Examples of several flattened, degrading control oocytes in sw alone at 44 h of aging (D) vs. cohorts treated with a sw solution of 25 µM SP600125 at 44 h; arrows mark precipitated inhibitor around intact oocytes. (F, G) A 25-µM or 33-µM seawater (sw) solution of the JNK inhibitor SP600125 (sp) or AS601245 (as), respectively, significantly reduces the intensity of the 48-kD phospho-JNK signal at 28 h of aging, compared with sw controls; bf = before GVBD is stimulated by incubating prophase-arrested oocytes in seawater. Scale bars = 50 µm.

Figure 4

Figure 5 (A, B) Normal patterns of the stimulatory phospho-T161 Cdc2 signal (A) and the inhibitory phospho-Y15 Cdc2. (B) signal of maturation-promoting factor (MPF) during oocyte aging; both phosphorylations indicate a marked drop in MPF activity around 20–28 h of aging, the time point when most uninseminated oocytes begin to degrade (cf. Fig. 2A). (C, D) Oocytes treated with a 25-µM or 33-µM solution of the JNK inhibitor SP600125 (sp) or AS601245 (as), respectively, maintain MPF activity longer during aging, compared with controls in seawater (sw) alone. Such results are consistent with the finding that MPF deactivation is temporally linked to oocyte degradation; BF = before GVBD is stimulated by incubating prophase-arrested oocytes in seawater.

Figure 5

Figure 6 (A–D) Protein synthesis inhibitors [25 µM anisomycin (aniso) or 100 µg/ml cycloheximide (chx)] retard oocyte degradation levels at 30 h of aging, compared with seawater (sw) controls lacking an inhibitor. (A) SW controls with numerous flattened and lysing oocytes at 36 h; (B, C) Intact cohort oocytes at 36 h after treatment with anisomycin (B) or cycloheximide (C). (D) Summary graph of data.